Ho, S. Membe, K. Cimon K, et al., (2008) Subcutaneous versus intravenous immunoglobulin for primary immu-nodeficiencies: Systematic review and economic evalua-tion. Ottawa: Canadian Agency for Drugs and Technolo-gies in Health.
 B. Hogy, H. O. Keinecke, M. Borte, (2005) Pharma-coeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. European Journal of Health Economics, 6(1), 24-29.
 J. Bjorkander, J. Nikoskelainen, H. Leibl, et al., (2006) Prospective open-label study of pharmacokinetics, effi-cacy and safety of a new 10% liquid intravenous immu-noglobulin in patients with hypo- or agammaglobulinemia. Vox Sanguinis, 90(4), 286-293.
 J. A. Mauskopf, S. D. Sullivan, L. Annemans, et al., (2007) Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices- budget impact analysis. Value in Health, 10, 336-347.
 National Statistics of Belgium, (2009) Population statis-tics. Available from: http://www.statbel.fgov.be, Accessed 5th May 2009.
 Prospective open-label study of pharmacokinetics, effi-cacy and safety of immune globulin intravenous (human), 10% TVR solution in patients with hypo- or agammag-lobulinemia. Final study report, study no. 160001.
 A clinical investigation to assess the safety and efficacy of immune globulin intravenous (human), 10% in subjects with primary immunodeficiency disorders. Interim study report, study no. 160101.
 Prospective open-label study of the efficacy and safety of immune globulin intravenous (human), 10% TVR solu-tion in adult subjects with chronic idiopathic thrombocy-topenic purpura. Final study report, study no. 160002.